Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Executive Summary

• Cardiol Therapeutics announced peer‑reviewed publication of positive Phase II ARCHER trial results for CardiolRx™ in ESC Heart Failure.
• In 109 acute myocarditis patients, CardiolRx™ significantly reduced left ventricular mass (‑9.2 g; p=0.0117) and showed favorable trends on multiple inflammation markers, with a safety profile comparable to placebo.
• The data bolster confidence in the ongoing pivotal Phase III MAVERIC trial for recurrent pericarditis, supporting CardiolRx™’s therapeutic potential across inflammatory heart diseases.

Key Details

• Study Design: Randomized, double‑blind, placebo‑controlled Phase II ARCHER trial; 109 patients with acute myocarditis; primary imaging endpoint was change in left ventricular (LV) mass measured by cardiac magnetic resonance (CMR).
• Efficacy Result: CardiolRx™ produced a statistically significant reduction in LV mass versus placebo of ‑9.2 g (p=0.0117), indicating decreased myocardial edema/inflammation.
• Secondary Findings: Observed decreases in left atrial remodeling and favorable trends across multiple CMR‑derived markers of myocardial inflammation; all results were consistent with improved structural outcomes.
• Safety: CardiolRx™ was reported as safe and well tolerated, with adverse event rates comparable to placebo.
• Clinical Relevance: LV mass reduction is widely regarded as a surrogate for reduced myocardial edema and better clinical prognosis in myocarditis, suggesting potential translation to pericarditis treatment.
• Implications for MAVERIC: The biological signals from ARCHER are directly relevant to the Phase III MAVERIC trial (recurrent pericarditis), reinforcing the mechanistic rationale for CardiolRx™ across the inflammatory myopericardial spectrum.
• Publication Details: Full article available at https://academic.oup.com/eschf/advance-article/doi/10.1093/eschf/xvaf034/8427108.

Notable Quotes

“ARCHER provides additional compelling clinical evidence that CardiolRx impacts the underlying biology of inflammatory heart disease and reduces inflammation‑driven structural damage in the heart, increasing our confidence in MAVERIC,” – David Elsley, President & CEO, Cardiol Therapeutics.